Company vTv Therapeutics Inc.

Equities

VTVT

US9183852048

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
23.63 ^USD	-0.29%		-12.37%	+105.48%

14/03	VTv Therapeutics Inc. Announces Board Changes	CI
13/03	VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.

Number of employees: 16

Managers	Title	Age	Since
Paul Sekhri CEO	Chief Executive Officer	66	01/22/01
Steven Tuch DFI	Director of Finance/CFO	56	08/22/08
Vanessa McDade ADM	Chief Administrative Officer	-	-
Thomas Strack CTO	Chief Tech/Sci/R&D Officer	-	02/11
Carmen Valcarce CTO	Chief Tech/Sci/R&D Officer	-	01/07/01
Richard Nelson BRD	Director/Board Member	54	16/20/16
Jennifer Freeman PRN	Corporate Officer/Principal	-	-
Barry Brown AUD	Comptroller/Controller/Auditor	63	01/22/01
Elizabeth M. Keiley LAW	General Counsel	58	01/23/01

Members of the board	Title	Age	Since
Srini Akkaraju Akkaraju BRD	Director/Board Member	56	27/02
Paul Sekhri CEO	Chief Executive Officer	66	01/22/01
Richard Nelson BRD	Director/Board Member	54	16/20/16
Raymond Cheong BRD	Director/Board Member	42	27/02
Fahed Al Marzooqi BRD	Director/Board Member	45	11/22/11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	577,349	0	0	49.45 %
Stock B	1	2,432,857	1,488,481 ( 61.18 %)	0

Name	Equities	%	Valuation
Ronald Perelman 37.53 %	912,982	37.53 %	21 M $
Samsara Biocapital LLC 10.92 %	265,620	10.92 %	6 M $
Group 42 Holding Ltd. 10.67 %	259,657	10.67 %	6 M $
MEDPACE HOLDINGS, INC. 5.546 %	134,938	5.546 %	3 M $
Baker Bros. Advisors LP 4.000 %	97,314	4.000 %	2 M $
Vanguard Global Advisers LLC 0.9667 %	23,519	0.9667 %	553 402 $
Paul Sekhri 0.7065 %	17,188	0.7065 %	404 434 $
John Fry 0.0627 %	1,525	0.0627 %	35 883 $
Richard Nelson 0.0617 %	1,500	0.0617 %	35 295 $
BlackRock Institutional Trust Co. NA 0.0551 %	1,341	0.0551 %	31 554 $

Name	Equities	%	Valuation
Ronald Perelman 2.499 %	577,108	2.499 %	240 654 $

vTv Therapeutics, Inc.

3980 Premier Drive Suite 310

27265, High Point

+336 841 0300

http://www.vtvtherapeutics.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VTV THERAPEUTICS INC.	+105.48%	57.49M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs